VEGFA and nonpapillary renal cell carcinoma: Currently, vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR)-directed therapies represent the standard of care for metastatic ccRCC, while the molecular sub-classifications of ccRCC remain to be fully elucidated (4).